Tricholoracetic acid

PreclinicalSmall molecule

CCombined Military Hospital Abbottabad

Tricholoracetic acid is one of 5 small molecule programs targeting Common Wart. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Common WartActive, not recruiting

Common WartPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Common Wart

#DrugCompanyPhaseTrials

Vistide

Trexall

Tricholoracetic acid

CCombined Military Hospital Abbottabad

Preclinical

1 4

Candida Antigen

UUniversity of Arkansas

Preclinical

1 5

CRYOTHERAPY

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Common Wart1 trial

Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts

Completed·—·N/A·NCT05712811·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tricholoracetic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tricholoracetic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tricholoracetic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Combined Military Hospital Abbottabad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCombined Military Hospital Abbottabad

Tricholoracetic acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Common Wart1 trial

References

Drug Info

Quick Facts

Related News